|
Recurrent Vaginal Cancer
Current Clinical Trials
Recurrence carries a grave prognosis. In a large series only five of fifty
patients with recurrence were salvaged by surgery or radiation therapy. All
five of these salvaged patients originally presented with stage I or II disease
and failed in the central pelvis.[1] Most recurrences are in the first 2 years
after treatment. In centrally recurrent vaginal cancers, some patients may be
candidates for pelvic exenteration or radiation therapy. Neither cisplatin nor mitoxantrone has
significant activity in recurrent or advanced squamous cell cancer. There is
no standard chemotherapy.
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with recurrent vaginal cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
References
-
Stock RG, Chen AS, Seski J: A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Gynecol Oncol 56 (1): 45-52, 1995.
[PUBMED Abstract]
Back to Top
< Previous Section | Next Section > |
